机译:用于MEDI3726的综合药代动力学和分解代谢评估的多原生物分析方法,一种抗前列腺特异性膜抗原吡咯唑二氮杂氮杂苄醇缀合物
AstraZeneca Integrated Bioanal Clin Pharmacol &
Quantitat Pha Clin Pharmacol &
Safety Sci R&
D San Francisco CA 94080 USA;
AstraZeneca Integrated Bioanal &
Clin Pharmacol San Francisco CA 94080 USA;
AstraZeneca Clin Pharmacol &
Quantitat Pharmacol Clin Pharmacol &
Safety Sci R&
D San Francisco CA 94080 USA;
PPD Labs Richmond VA 23230 USA;
PPD Labs Richmond VA 23230 USA;
PPD Labs Richmond VA 23230 USA;
PPD Labs Richmond VA 23230 USA;
PPD Labs Richmond VA 23230 USA;
PPD Labs Richmond VA 23230 USA;
PPD Labs Richmond VA 23230 USA;
PPD Labs Richmond VA 23230 USA;
PPD Labs Richmond VA 23230 USA;
AstraZeneca Clin Pharmacol &
Quantitat Pharmacol Clin Pharmacol &
Safety Sci R&
D San Francisco CA 94080 USA;
AstraZeneca Integrated Bioanal Clin Pharmacol &
Quantitat Pha Clin Pharmacol &
Safety Sci R&
D San Francisco CA 94080 USA;
AstraZeneca Integrated Bioanal Clin Pharmacol &
Quantitat Pha Clin Pharmacol &
Safety Sci R&
D San Francisco CA 94080 USA;
机译:用于MEDI3726的综合药代动力学和分解代谢评估的多原生物分析方法,一种抗前列腺特异性膜抗原吡咯唑二氮杂氮杂苄醇缀合物
机译:抗体-药物结合物:潜在客户优化和选择中的综合生物分析和生物处置评估
机译:治疗单克隆抗体和抗体 - 药物缀合物的生物分析方法:近期进步和未来观点综述
机译:抗体-药物结合物的药代动力学评估的ADME注意事项和生物分析策略
机译:Medi3726的综合药代动力学和分解代谢评估的多原生物分析方法,一种抗前列腺特异性膜抗原吡咯唑二苯并二氮杂二氮杂苯并二苯并二氮杂氮